Company research / CTSO

Cytosorbents Corp (CTSO)

CIK 0001175151 · Nasdaq · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Cytosorbents Corp reported revenue of $37.06M. Revenue grew 4.1% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $37.22M.

Key ratios (year ended 2025-12-31)

71.5%
Gross margin
-39.8%
Operating margin
-22.1%
Net margin
-138.9%
Return on year-end equity
4.1%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-23

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Revenue$37.22M$37.06M$35.59Mn/an/an/a$31.08Mn/an/an/a$34.69M
Cost of Revenue$10.57M$10.57M$10.71Mn/an/an/a$9.13Mn/an/an/a$13.96M
Gross Profit$26.65M$26.49M$24.89Mn/an/an/a$21.95Mn/an/an/a$20.73M
R&D Expensen/an/an/an/an/an/a$15.73Mn/an/an/a$15.12M
Operating Income-$12.93M-$14.75M-$16.45Mn/an/an/a-$31.95Mn/an/an/a-$31.52M
Depreciation & Amortizationn/a$1.23M$1.33Mn/an/an/a$1.46Mn/an/an/a$882.6K
EBITDAn/a-$13.52M-$15.12Mn/an/an/a-$30.49Mn/an/an/a-$30.64M
Net Income-$18.21M-$8.20M-$20.72Mn/an/an/a-$29.25Mn/an/an/a-$32.81M
EPS (Diluted)n/a-$0.13-$0.38n/an/an/a-$0.65n/an/an/a-$0.75
Total Assets$37.96M$44.18M$47.37M$47.80M$53.43M$47.07M$52.96M$47.58M$52.44M$57.46M$63.23M
Total Liabilities$38.71M$38.28M$36.27M$34.66M$36.00M$27.44M$29.48M$28.76M$27.98M$27.52M$27.86M
Long-Term Debt$17.24Mn/an/an/an/an/a$5.04Mn/an/an/an/a
Shareholders' Equity-$751.0K$5.90M$11.11M$13.14M$17.43M$19.63M$23.48M$18.81M$24.46M$29.94M$35.37M
Cash & Equivalents$4.41M$6.25M$3.28Mn/an/an/a$14.13Mn/an/an/a$22.14M
Operating Cash Flow-$9.15M-$12.38M-$14.43Mn/an/an/a-$21.66Mn/an/an/a-$28.23M
Capital Expenditures$150.0K$164.0K$284.0Kn/an/an/a$538.1Kn/an/an/a$6.09M
Free Cash Flow-$9.30M-$12.54M-$14.71Mn/an/an/a-$22.19Mn/an/an/a-$34.32M
Shares Outstanding62.84M62.80M54.83Mn/an/an/a54.24Mn/an/an/a43.64M
Weighted Average Diluted Sharesn/a62.23M54.43Mn/an/an/a44.66Mn/an/an/a43.57M
EPS (Basic)n/a-$0.13-$0.38n/an/an/a-$0.65n/an/an/a-$0.75

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView